EGFR inhibition with cetuximab in colorectal cancer underwent a concurrent transformation from benefit across the patient population (19), to those without KRAS mutations (20, 21), and now even more limited to those with left-sided pan-RAS wildtype tumors (22, 23). This evidence concerns the gene EGFR and colorectal cancer.